Your AI-Trained Oncology Knowledge Connection!

Video

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

Author(s):

Peter Langmuir, MD

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca on Vandetanib in Medullary Thyroid Cancer

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Shilpa Gupta, MD, director of Genitourinary Medical Oncology at the Taussig Cancer Institute and co-leader of the Genitourinary Oncology Program in the Department of Hematology and Medical Oncology, Cleveland Clinic; as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center
Hyun-Woong Cho, MD, PhD, Department of Obstetrics and Gynecology, Korea University College of Medicine
SHAH
Timothy S. Fenske, MD, MS
Sheela Rao, MBBS, MD, FRCP
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD
Related Content
Penpulimab for Recurrent or Metastatic NPC | Image Credit: ©shahzaib – stock.adobe.com
March 18th 2025

Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Salivary Gland Cancer | Image Credit: © shahzaib – stock.adobe.com
March 14th 2025

AVA6000 Generates Early Efficacy, Is Safe in Advanced Salivary Gland Cancers

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
September 2nd 2021

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Image Credit: Katsyarina – stock.adobe.com
March 6th 2025

Versamune HPV–Based Immunotherapy Combo Demonstrates Benefit in Advanced HPV-Associated Cancers

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.
March 1st 2025

The OncFive: Top Oncology Articles for the Week of 2/23